2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Biological Processes, Pathogenesis, Hematopoiesis, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Infectious Diseases, Viral, Research, Fundamental Science, Translational Research, Clinical Research, Health Disparities Research, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

4671 Developing a humanized mouse model of sickle cell anemia for preclinical therapeutic evaluation

Fengxing Gu, Ruili Lv2, Jiansu Zhang3, Jiangfeng Yuan4, Xiaofei Zhou5, Hannah Horton6
1 Biocytogen Pharmaceuticals (Beijing), Beijing, China
2 Biocytogen Pharmaceuticals (Beijing), Beijing, China
3 Biocytogen Pharmaceuticals (Beijing), Beijing, China
4 Biocytogen Pharmaceuticals (Beijing), Beijing, China
5 Biocytogen Pharmaceuticals (Beijing), Beijing, China
6 Biocytogen, Waltham, United States

Introduction: Sickle cell anemia is an inherited hemoglobinopathy driven by a pathogenic variant in the human β-globin gene (HBB<sup>S</sup>). Mutant hemoglobin S undergoes polymerization under deoxygenated conditions, triggering red blood cell sickling, chronic hemolysis, vaso-occlusion, and progressive multi-organ injury. Current investigational therapeutics, including oligonucleotides, gene modifiers, and small molecules, require physiologically relevant animal models carrying human globin loci to recapitulate disease pathology and support efficacy testing.

Methods: The mouse Hba-a1/Hba-a2 genes were replaced with human HBA1/HBA2 to generate B-hHBA1/hHBA2 mice (129S2). The mouse Hbb-bs/Hbb-bt genes were replaced with human HBG1/HBG2/HBD/HBBs to generate B-hHBG1/hHBG2/hHBD/hHBBs mice. B-hHBA1/hHBA2/hHBG1/hHBG2/hHBD/hHBBs mice (B6; 129S) were produced by intercrossing the two single humanized strains. Hematology panel testing, serum biochemistry, and peripheral blood smear analysis were performed to characterize the model.

Results: The complete blood count test results reveal that, in comparison to wild-type control mice, there is a substantial decline in RBC, HGB, HCT, and PLT in sickle cell anemia mice. Conversely, these mice exhibit a significant increase in WBC, RDW, NRBC#, NRBC%, RET#, and RET%. Biochemistry analysis shows a substantial increase in ALT, AST, and TBIL in sickle cell anemia mice. The blood smear analysis results showed that sickle cell anemia mice exhibited a distinct and stable sickle red blood cell phenotype.

Conclusions: This compound humanized mouse strain carries the full set of human α-globin, fetal globin, δ-globin, and sickle mutant β-globin genes and recapitulates core hematologic, biochemical, and cellular hallmarks of human sickle cell anemia. This model represents a powerful in vivo platform for preclinical efficacy and safety evaluation of novel therapies targeting sickle cell disease.

Hannah Horton: No relevant conflicts of interest to declare.